A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI Community, 

As the year comes to a close, I’m proud to share the whirlwind of activity in the FAPI space over the last several months.

Last month, I participated in three forums that highlighted FAP advancements.  On November 7, I was invited to a roundtable discussion sponsored by Perceptive and Lantheus on “FAPI-PET imaging & theranostics: A new era in targeting cancer and fibrotic diseases”.  SOFIE was a silver sponsor of the next two events, the 2024 Associate Technical Affiliates of Western Michigan (ATAWM) and Central Chapter Society of Nuclear Medicine and Molecular Imaging (CCSNMMI) Michigan Road Show and the ICPO Theranostics Virtual Summit . It is a pleasure and privilege to be a part of these events so critical to broadening and educating our FAPI community and, importantly, challenge our perspectives.

Our 18F-FAPI-74 Phase 2 clinical study in gastrointestinal cancers in nearing completion and our team is working diligently on Phase 3 planning, which , pending final FDA review, is expected to be launched in late 2025.

We would like to thank our Global Outreach Program community for submitting your annual Progress Reports.  It has been instructive to learn more about your research programs utilizing FAPI, and we wish you continued progress in your efforts.

As always, thank you for reading our newsletter. We value your suggestions on how this newsletter can become a better resource for you. Wishing everyone a wonderful holiday season and a happy new year!

Sherly Mosessian, Ph.D.

– Sherly Mosessian, Ph.D., Chief Scientific Officer

FAPI-74 CLINICAL DEVELOPMENT UPDATE

Q4 2024 FAPI Clin Dev Program

PUBLICATION HIGHLIGHTS

Each newsletter will feature recent FAPI publications.

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

J Nucl Med. 2024 Dec 3

Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models

Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models

Int J Mol Sci. 2024 Oct 28

Impact of fat intake on [18F]AIF-NOTA-FAPI-04 uptake in normal abdominal organs

Impact of fat intake on [18F]AIF-NOTA-FAPI-04 uptake in normal abdominal organs

Front Med (Lausanne). 2024 Nov 7

FAPI OUTREACH PROGRAM

Join us in advancing the frontier of molecular imaging through the FAPI Outreach Program

SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically focusing on Fibroblast Activation Protein Inhibitor (FAPI) studies. This program seeks to engage with healthcare professionals, researchers, and the broader community to share knowledge, advancements, and the potential impact of FAPI in diagnostic and therapeutic applications.

*GE Healthcare licensed products and regions will be ready for new application reviews in April.

Copyright 2024 SOFIE CO. / ITHERANOSTICS INC. (21000 Atlantic Blvd. Suite 730  Dulles, VA  20166) all rights reserved.  The text or images in the newsletter may not be copied or distributed without prior permission of SOFIE. The SOFIE logo is a registered trademark of SOFIE CO. / ITHERANOSTICS INC., in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners. You have received this mail because you have subscribed for a newsletter at www.sofie.com or because you are an existing client or partner of SOFIE. If you no longer wish to receive these emails, click here to opt out.  This newsletter is meant to serve as an informational document as a service to our customers. The content or material provided is for informational purposes only and should and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. SOFIE does not offer personalized medical advice or patient-specific treatment advice.